Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.

Journal of personalized medicine·2026
Same author

Early Discharge Clinic: A Quality Improvement Initiative to Create a Safe and Efficient Model for Intensive Outpatient Management of Hematologic Malignancies.

JCO oncology practice·2026
Same author

Stuck in traffic: a bispecific antibody-mediated immune re-engagement after allogeneic stem cell transplantation.

Haematologica·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Oxygenation status with left lateral vs supine position in bariatric patients undergoing esophagogastroduodenoscopy (EGD): safe or not?

Surgical endoscopy·2026
Same author

IFI16 senses and protects stalled replication forks.

Molecular cell·2026
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

High-dose chemotherapy and multiple sclerosis.

Daniel Harrison1, Douglas E Gladstone

  • 1Department of Neurology, The Johns Hopkins Multiple Sclerosis Center, Johns Hopkins University School of Medicine, USA.

Current Opinion in Oncology
|December 21, 2010
PubMed
Summary
This summary is machine-generated.

High-dose chemotherapy shows potential for treating refractory multiple sclerosis (MS). While evidence is still developing, chemotherapy without stem cell rescue may offer a safer alternative for managing this autoimmune disease.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jun 5, 2026

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neurology
  • Immunology
  • Oncology

Background:

  • Multiple sclerosis (MS) is a debilitating autoimmune disease of the central nervous system.
  • Current immunomodulatory treatments offer limited control for MS.
  • High-dose chemotherapy (HDC) is being explored for treatment-refractory MS.

Purpose of the Study:

  • To review recent advancements and controversies in high-dose chemotherapy for multiple sclerosis.
  • To evaluate the efficacy and safety of HDC with and without stem cell rescue for MS.

Main Methods:

  • Review of recent scientific literature on high-dose chemotherapy for multiple sclerosis.
  • Analysis of studies investigating high-dose chemotherapy with stem cell rescue (HDC-SCR).
  • Examination of trials involving high-dose chemotherapy without stem cell rescue (HDC-noSCR).

Main Results:

  • Conclusive evidence for HDC-SCR efficacy is limited by non-uniform patient populations and protocols.
  • Significant toxicity associated with HDC-SCR has reduced enthusiasm for its use.
  • HDC-noSCR is a less toxic alternative, preventing re-infusion of autoreactive lymphocytes.

Conclusions:

  • Randomized clinical trials are necessary to validate both HDC-SCR and HDC-noSCR for MS treatment.
  • Both HDC approaches may reduce MS disease activity.
  • HDC-noSCR presents a more favorable safety profile and could be a significant advancement in MS therapy.